Roche Archives -

Roche adds to pipeline with Poseida, Kiniksa deals

Phil Taylor CAR-T therapies, Genentech, Kiniksa Pharmaceuticals, partnering, Poseida Therapeutics, prurigo nodularis, Roche 0 Comment

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline

Roche adds to pipeline with Poseida, Kiniksa deals

https://pharmaphorum.com/news/roche-adds-to-pipeline-with-poseida-kiniksa-deals/

Market Access/ News/ News/ News/ Sales and Marketing

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

Phil Taylor biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis 0 Comment

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/

News/ News/ R&D

AC Immune tries to resurrect crenezumab with new data delve

Phil Taylor AC Immune, Alzheimer's disease, crenezumab, Roche 0 Comment

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the

AC Immune tries to resurrect crenezumab with new data delve

https://pharmaphorum.com/news/ac-immune-tries-to-resurrect-crenezumab-with-new-data-delve/

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

News/ News/ News/ Oncology/ R&D

Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings

Phil Taylor drug delivery, immuno-oncology, Oncology, Roche, Tecentriq 0 Comment

Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous

Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings

https://pharmaphorum.com/news/roche-scores-phase-3-win-for-subcutaneous-tecentriq-eyes-filings/

Oncology/ Views & Analysis/ Views and analysis

Oncology market dominance: As easy as ADC?

Ben Hargreaves antibody-drug conjugates, Keytruda, Pfizer, Roche 0 Comment

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing

Oncology market dominance: As easy as ADC?

https://pharmaphorum.com/oncology/oncology-market-dominance-as-easy-as-adc/

Market Access/ News/ News/ News/ Oncology

Roche’s fast-growing eye drug Vabysmo set for EU approval

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo 0 Comment

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

News/ News/ Sales and Marketing

Roche CEO Severin Schwan to stand down after 14 years

Phil Taylor diagnostics, Pharmaceuticals, Roche, senior management, strategy 0 Comment

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently

Roche CEO Severin Schwan to stand down after 14 years

https://pharmaphorum.com/news/roche-ceo-severin-schwan-to-stand-down-after-14-years/

Market Access/ News/ News/ News/ Oncology

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa 0 Comment

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

https://pharmaphorum.com/news/az-daiichi-challenge-roche-with-eu-okay-for-earlier-use-of-enhertu/

Market Access/ News/ News/ News/ Oncology

Byondis cues up US, EU decisions on breast cancer ADC in 2023

Phil Taylor AstraZeneca, breast cancer, Byondis, Daiichi Sankyo, Enhertu, her2, Kadcyla, Oncology, Roche 0 Comment

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible

Byondis cues up US, EU decisions on breast cancer ADC in 2023

https://pharmaphorum.com/news/byondis-cues-up-us-eu-decisions-on-breast-cancer-adc-in-2023/

Trending

Roche

Login